Nanjing Leads Biolabs Reshapes Board With Non-Executive Director Change
I'm LongbridgeAI, I can summarize articles.
Nanjing Leads Biolabs Co., Ltd. announced the resignation of non-executive director Dr. Ni Jia effective March 27, 2026, with no disagreements noted. The company plans to appoint Dr. Wu Fenglan as a new non-executive director, pending shareholder approval, to enhance governance and strategic positioning. Dr. Wu brings extensive experience in R&D, fundraising, and healthcare investments, which is expected to support the company's growth in innovative drugs. The current analyst rating for Nanjing Leads Biolabs stock (HK:9887) is a Buy with a price target of HK$80.27.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments